癌症研究
半乳糖凝集素
生物
细胞毒性T细胞
细胞生物学
免疫学
免疫系统
体外
生物化学
作者
Inna M. Yasinska,Svetlana S. Sakhnevych,Ludmila Pavlova,Anette Teo Hansen Selnø,Ana Maria Teuscher Abeleira,Ouafa Benlaouer,Isabel Silva,Marianne Mosimann,Luca Varani,Marco Bardelli,Rohanah Hussain,Giuliano Siligardi,Dietmar Cholewa,Steffen Berger,Bernhard F. Gibbs,Yuri A. Ushkaryov,Elizaveta Fasler-Kan,Elena Klenova,Vadim V. Sumbayev
标识
DOI:10.3389/fimmu.2019.01594
摘要
Human cancer cells operate a variety of effective molecular and signalling mechanisms which allow them to escape host immune surveillance and thus progress the disease. We have recently reported that the immune receptor Tim-3 and its natural ligand galectin-9 are involved in the immune escape of human acute myeloid leukaemia cells. These cells use the neuronal receptor latrophilin 1 (LPHN1) and its ligand fibronectin leucine rich transmembrane protein 3 (FLRT3, and possibly other ligands) to trigger the pathway. We hypothesised that the Tim-3-galectin-9 pathway may be involved in the immune escape of cancer cells of different origins. We found that studied breast tumours expressed significantly higher levels of both galectin-9 and Tim-3 compared to healthy breast tissues of the same patients and that these proteins were co-localised. Increased levels of LPHN2 and expressions of LPHN3 as well as FLRT3 were also detected in breast tumour cells. Activation of this pathway facilitated the translocation of galectin-9 onto the tumour cell surface, however no secretion of galectin-9 by tumour cells was observed. Surface-based galectin-9 was able to protect breast carcinoma cells against cytotoxic T cell-induced death. Furthermore, we found that cell lines from brain, colorectal, kidney, blood/mast cell, liver, prostate, lung and skin cancers expressed detectable amounts of both Tim-3 and galectin-9 proteins. The majority of cell lines expressed one of the LPHN isoforms and FLRT3. We conclude that the Tim-3-galectin-9 pathway is operated by a wide range of human cancer cells and is possibly involved in prevention of anti-tumour immunity.
科研通智能强力驱动
Strongly Powered by AbleSci AI